I'm LongbridgeAI, I can summarize articles.Cantor Fitzgerald analyst Kristen Kluska reiterated a Buy rating on Eupraxia Pharmaceuticals (EPRX) with a $19.00 price target. Kluska, a 5-star analyst in the Healthcare sector, maintains this stance despite the broader market consensus showing a Strong Buy with an average price target of $17.01.
Cantor Fitzgerald analyst Kristen Kluska reiterated a Buy rating on Eupraxia Pharmaceuticals yesterday and set a price target of $19.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Kluska is a 5-star analyst with an average return of 23.8% and a 48.57% success rate. Kluska covers the Healthcare sector, focusing on stocks such as Celldex, Codexis, and Eupraxia Pharmaceuticals.
Currently, the analyst consensus on Eupraxia Pharmaceuticals is a Strong Buy with an average price target of $17.01.